Ascendis Pharma A (ASND) Cash & Equivalents (2012 - 2026)

Ascendis Pharma A has reported Cash & Equivalents for 15 years, with the latest figure at $670.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 23.1% year-over-year to $670.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.6 million (up 23.1% YoY) and the FY2025 annual result came in at $717.1 million, up 19.93% from the prior year.
• Cash & Equivalents eased to $670.6 million in Q1 2026 per ASND's latest filing, from $717.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $848.1 million in Q1 2022 and troughed at $278.6 million in Q2 2024.
• A 5-year average of $560.9 million and a median of $559.2 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 40.17% in 2023, then soared 100.74% in 2025.
• Over 5 years, Cash & Equivalents stood at $453.8 million in 2022, then declined by 7.01% to $421.9 million in 2023, then jumped by 41.71% to $597.9 million in 2024, then grew by 19.93% to $717.1 million in 2025, then dropped by 6.48% to $670.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $670.6 million, $717.1 million, and $630.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.